What is claimed is:

1. A power supply for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathorasic blood vessels and for providing antibradycardia pacing energy to the heart, the power supply comprising:

a capacitor subsystem for storing the anti-bradycardia pacing energy for delivery to the patient's heart; and

- a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.
- 2. The power supply of claim 1, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 100 volts.
- 3. The power supply of claim 2, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 25 volts.

4. The power supply of claim 2, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 25 volts to approximately 50 volts.

5

- 5. The power supply of claim 2, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 50 volts to approximately 75 volts.
- 6. The power supply of claim 2, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 75 volts to approximately 100 volts.
- 7. The power supply of claim 1, wherein the antibradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

20

8. The power supply of claim 7, wherein the antibradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.

- 9. The power supply of claim 7, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.
- 10. The power supply of claim 7, wherein the antibradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.
- 11. The power supply of claim 7, wherein the antibradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.
- 12. The power supply of claim 1, wherein the antibradycardia pacing energy comprises a monophasic waveform further comprising a voltage waveform that is either positive or negative in polarity.
- 13. The power supply of claim 12, wherein the monophasic waveform further comprises a tilt of approximately 5% to approximately 95%.

14. The power supply of claim 13, wherein the tilt is approximately 50%.

5

- 15. The power supply of claim 1, wherein the antibradycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 20 to approximately 120 stimuli/minute.
- 16. The power supply of claim 15, wherein the monophasic waveform is provided after a patient's heart rate is equal or less than approximately 20 beats/minute.
- 17. A voltage output system for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathorasic blood vessels and for providing anti-bradycardia pacing energy to the heart, the power supply comprising:

20

an energy storage system for storing the antibradycardia pacing energy for delivery to the patient's heart; and an energy source system electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.

5

- 18. The voltage output system of claim 17, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 100 volts.
- 19. The voltage output system of claim 18, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 25 volts.
- 20. The voltage output system of claim 18, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 25 volts to approximately 50 volts.

20

21. The voltage output system of claim 18, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 50 volts to approximately 75 volts.

22. The voltage output system of claim 18, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 75 volts to approximately 100 volts.

5

- 23. The voltage output system of claim 17, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.
- 24. The voltage output system of claim 23, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.
- 25. The voltage output system of claim 23, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

20

26. The voltage output system of claim 23, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

- 27. The voltage output system of claim 23, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.
- 28. The voltage output system of claim 17, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.
- 29. The voltage output system of claim 28, wherein the positive voltage portion further comprises a tilt of approximately 5% to approximately 95%.
- 30. The voltage output system of claim 29, wherein the tilt is approximately 50%.
- 31. The voltage output system of claim 17, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 20 to approximately 120 stimuli/minute.

5

32.

33. An implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib within a patient, the implantable cardioverter-defibrillator comprising:

the monophasic waveform is provided after a patient's heart

rate is equal or less than approximately 20 beats/minute.

The voltage output system of claim 31, wherein

a housing having an electrically conductive surface on an outer surface of the housing;

- a lead assembly electrically coupled to the housing and having an electrode, wherein the lead assembly does not directly contact the patient's heart or reside in the intrathorasic blood vessels;
- a capacitor subsystem located within the housing and electrically coupled to the electrically conductive surface and the electrode for storing anti-bradycardia pacing energy and for delivering the anti-bradycardia pacing energy to the patient's heart through the electrically conductive surface and the electrode; and
- a battery subsystem electrically coupled to the capacitor subsystem for providing the anti-bradycardia pacing energy to the capacitor subsystem.

34.

claim 33, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 100 volts.

The implantable cardioverter-defibrillator of

- 35. The implantable cardioverter-defibrillator of claim 34, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 25 volts.
- 36. The implantable cardioverter-defibrillator of claim 34, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 25 volts to approximately 50 volts.
- 37. The implantable cardioverter-defibrillator of claim 34, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 50 volts to approximately 75 volts.
- 38. The implantable cardioverter-defibrillator of claim 34, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 75 volts to approximately 100 volts.

- 39. The implantable cardioverter-defibrillator of claim 33, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.
- 40. The implantable cardioverter-defibrillator of claim 39, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 10 milliseconds.
- 41. The implantable cardioverter-defibrillator of claim 39, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.

20

42. The implantable cardioverter-defibrillator of claim 39, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.

- 43. The implantable cardioverter-defibrillator of claim 39, wherein the anti-bradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.
- 44. The implantable cardioverter-defibrillator of claim 33, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.
- 45. The implantable cardioverter-defibrillator of claim 44, wherein the positive voltage portion further comprises a tilt that is approximately 5% to approximately 95%.
- 46. The implantable cardioverter-defibrillator of claim 45, wherein the tilt is approximately 50%.
- 47. The implantable cardioverter-defibrillator of claim 33, wherein the anti-bradycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 20 to approximately 120 stimuli/minute.

5

- 48. The implantable cardioverter-defibrillator of claim 47, wherein the monophasic waveform is provided after a patient's heart rate is equal or less than approximately 20 beats/minute.
- 49. A method for supplying power for an implantable cardioverter-defibrillator for subcutaneous positioning between the third rib and the twelfth rib and using a lead system that does not directly contact a patient's heart or reside in the intrathorasic blood vessels and for providing anti-bradycardia pacing energy to the heart, the method comprising:

generating anti-bradycardia pacing energy;
storing the anti-bradycardia pacing energy; and
delivering the anti-bradycardia pacing energy to the
patient's heart.

50. The method of claim 49, wherein the antibradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately .1 volts to approximately 100 volts.

5

51.

approximately 25 volts.

approximately 50 volts.

52. The method of claim 50, wherein the antibradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 25 volts to

The method of claim 50, wherein the anti-

bradycardia pacing energy comprises a monophasic waveform

having a peak voltage that is approximately .1 volts to

- 53. The method of claim 50, wherein the antibradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 50 volts to approximately 75 volts.
- 54. The method of claim 50, wherein the antibradycardia pacing energy comprises a monophasic waveform having a peak voltage that is approximately 75 volts to approximately 100 volts.
- 55. The method of claim 49, wherein the antibradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 1 millisecond to approximately 40 milliseconds.

- 56. The method of claim 55, wherein the antibradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 2 milliseconds to approximately 10 milliseconds.
- 57. The method of claim 55, wherein the antibradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 10 milliseconds to approximately 20 milliseconds.
- 58. The method of claim 55, wherein the antibradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 20 milliseconds to approximately 30 milliseconds.
- 59. The method of claim 55, wherein the antibradycardia pacing energy comprises a monophasic waveform having a pulse width that is approximately 30 milliseconds to approximately 40 milliseconds.
- 60. The method of claim 49, wherein the antibradycardia pacing energy comprises a monophasic waveform that is either positive or negative in polarity.

- 61. The method of claim 60, wherein the positive voltage portion further comprises a tilt of approximately 5% to approximately 95%.
- 62. The method of claim 61, wherein the tilt is approximately 50%.
- 63. The method of claim 49, wherein the antibradycardia pacing energy comprises a monophasic waveform that is provided at a rate of approximately 20 to approximately 120 stimuli/minute.
- 64. The method of claim 63, wherein the monophasic waveform is provided after a patient's heart rate is equal or less than approximately 20 beats/minute.
- 65. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the third and fifth ribs.
- 66. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the fourth and sixth ribs.

- 67. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the sixth and eighth ribs.
- 68. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the eighth and tenth ribs.
- 69. The method of claim 49, wherein the implantable cardioverter-defibrillator is positioned subcutaneously between the tenth and twelfth ribs.